Surgery versus intra-arterial therapy for neuroendocrine liver metastasis: A multicenter international analysis

Annals of Surgical Oncology

Volumn 18, Issue 13, 2011, Pages 3657-3665

  Mayo, Skye C ^a   De Jong, Mechteld C ^a   Bloomston, Mark ^b   Pulitano, Carlo ^c   Clary, Bryan M ^d   Reddy, Srinevas K ^d   Clark Gamblin, T ^e   Celinski, Scott A ^e   Kooby, David A ^f   Staley, Charles A ^f   Stokes, Jayme B ^h   Chu, Carrie K ^f   Arrese, David ^b   Ferrero, Alessandro ⁱ   Schulick, Richard D ^a   Choti, Michael A ^a   Geschwind, Jean Francois H ^a   Strub, Jennifer ^g   Bauer, Todd W ^h   Adams, Reid B ^h   Aldrighetti, Luca ^c   Mentha, Gilles ^g   Capussotti, Lorenzo ⁱ   Pawlik, Timothy M ^a   more..

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF PITTSBURGH   (United States)

^f EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^h UNIVERSITY OF VIRGINIA   (United States)

ⁱ MAURIZIANO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

OCTREOTIDE; YTTRIUM 90;

ADULT; ARTICLE; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL ASSESSMENT; FEMALE; HUMAN; INTERMETHOD COMPARISON; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROENDOCRINE TUMOR; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS CANCER; PROPORTIONAL HAZARDS MODEL; SMALL INTESTINE CANCER; STATISTICAL SIGNIFICANCE; TUMOR VOLUME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; FOLLOW-UP STUDIES; HEPATECTOMY; HUMANS; INJECTIONS, INTRA-ARTERIAL; INTERNATIONAL AGENCIES; LIVER NEOPLASMS; MALE; MIDDLE AGED; MORBIDITY; NEOPLASM RECURRENCE, LOCAL; NEUROENDOCRINE TUMORS; PROGNOSIS;

EID: 82955163219     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-011-1832-y     Document Type: Article

References (32)

1. IM Modlin KD Lye M Kidd 2003 A 5-decade analysis of 13, 715 carcinoid tumors Cancer. 97 934 959 12569593 10.1002/cncr.11105 (Pubitemid 36173145)
2. RS Chamberlain D Canes KT Brown, et al. 2000 Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg. 190 432 445 10757381 10.1016/S1072-7515(00)00222-2 1:STN:280:DC%2BD3c3hvVejtQ%3D%3D (Pubitemid 30181109)
3. H Chen JM Hardacre A Uzar, et al. 1998 Isolated liver metastases from neuroendocrine tumors: does resection prolong survival? J Am Coll Surg. 187 88 92 9660030 10.1016/S1072-7515(98)00099-4 1:STN:280:DyaK1czitFCltQ%3D%3D (Pubitemid 28303537)
4. CD Knox CD Anderson LW Lamps, et al. 2003 Long-term survival after resection for primary hepatic carcinoid tumor Ann Surg Oncol. 10 1171 1175 14654473 10.1245/ASO.2003.04.533 (Pubitemid 40486812)
5. H Nave E Mossinger H Feist, et al. 2001 Surgery as primary treatment in patients with liver metastases from carcinoid tumors: a retrospective, unicentric study over 13 years Surgery. 129 170 175 11174710 10.1067/msy.2001.110426 1:STN:280:DC%2BD3M7ltVOitw%3D%3D (Pubitemid 32158579)
6. JM Sarmiento G Heywood J Rubin, et al. 2003 Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival J Am Coll Surg. 197 29 37 12831921 10.1016/S1072-7515(03)00230-8 (Pubitemid 36759176)
7. D O'Toole O Hentic O Corcos, et al. 2004 Chemotherapy for gastro-enteropancreatic endocrine tumours Neuroendocrinology 80 Suppl 1 79 84 15477723 10.1159/000080747 (Pubitemid 39382375)
8. PF Engstrom PT Lavin CG Moertel, et al. 1984 Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor J Clin Oncol. 2 1255 1259 6238136 1:STN:280:DyaL2M%2Fjt1yjtA%3D%3D (Pubitemid 15202700)
9. S Scigliano R Lebtahi F Maire, et al. 2009 Clinical and imaging follow-up after exhaustive liver resection of endocrine metastases: a 15-year monocentric experience Endocr Relat Cancer. 16 977 990 19470616 10.1677/ERC-08-0247 1:STN:280:DC%2BD1MrmslWhsw%3D%3D
10. JG Touzios JM Kiely SC Pitt, et al. 2005 Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg. 241 776 783 15849513 10.1097/01.sla.0000161981.58631.ab (Pubitemid 40604923)
11. SC Mayo MC de Jong C Pulitano, et al. 2010 Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis Ann Surg Oncol. 17 3129 3136 20585879 10.1245/s10434-010-1154-5
12. AS Ho J Picus MD Darcy, et al. 2007 Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors AJR Am J Roentgenol. 188 1201 1207 17449759 10.2214/AJR.06.0933 (Pubitemid 46668497)
13. E Liapi JF Geschwind JA Vossen, et al. 2008 Functional MRI evaluation of tumor response in patients with neuroendocrine hepatic metastasis treated with transcatheter arterial chemoembolization AJR Am J Roentgenol. 190 67 73 18094295 10.2214/AJR.07.2550
14. E Liapi CC Georgiades K Hong, et al. 2007 Transcatheter arterial chemoembolization: current technique and future promise Tech Vasc Interv Radiol. 10 2 11 17980314 10.1053/j.tvir.2007.08.008 (Pubitemid 350008078)
15. A Saxena TC Chua L Bester, et al. 2010 Factors predicting response and survival after yttrium-90 radioembolization of unresectable neuroendocrine tumor liver metastases: a critical appraisal of 48 cases Ann Surg. 251 910 916 20395859 10.1097/SLA.0b013e3181d3d24a
16. S Gupta JC Yao K Ahrar, et al. 2003 Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M. D. Anderson experience Cancer J. 9 261 267 12967136 10.1097/00130404- 200307000-00008
17. A Roche BV Girish T de Baere, et al. 2003 Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumors Eur Radiol. 13 136 140 12541121 (Pubitemid 36790502)
18. BK Eriksson EG Larsson BM Skogseid, et al. 1998 Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors Cancer. 83 2293 2301 9840528 10.1002/(SICI)1097-0142(19981201)83:11<2293::AID-CNCR8>3.0. CO;2-E 1:STN:280:DyaK1M%2FlsValsQ%3D%3D (Pubitemid 28533498)
19. S Gupta MM Johnson R Murthy, et al. 2005 Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival Cancer. 104 1590 1602 16134179 10.1002/cncr.21389 (Pubitemid 41437421)
20. SM Strasberg 2005 Nomenclature of hepatic anatomy and resections: a review of the Brisbane 2000 system J Hepatobiliary Pancreat Surg. 12 351 355 16258801 10.1007/s00534-005-0999-7 (Pubitemid 41662443)
21. P Therasse EA Eisenhauer J Verweij 2006 RECIST revisited: a review of validation studies on tumour assessment Eur J Cancer. 42 1031 1039 16616487 10.1016/j.ejca.2006.01.026 1:STN:280:DC%2BD283nt1antQ%3D%3D
22. EA Eisenhauer P Therasse J Bogaerts, et al. 2009 New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer. 45 228 247 19097774 10.1016/j.ejca.2008.10.026 1:STN:280: DC%2BD1M%2Fgs12rug%3D%3D
23. EL Kaplan P Meier 1958 Nonparametric estimation from incomplete observations J Am Stat Assoc. 53 457 481 10.2307/2281868
24. D Cox 1972 Regression models and life tables J R Stat Soc B. 34 187 220
25. PR Rosenbaum DB Rubin 1983 The central role of the propensity score in observational studies for causal effects Biometrika. 70 41 55 10.1093/biomet/70.1.41
26. DB Rubin 1997 Estimating causal effects from large data sets using propensity scores Ann Intern Med. 127 8 Pt 2 757 763 9382394 1:STN:280:DyaK2svmvVKitQ%3D%3D (Pubitemid 27446562)
27. RB D'Agostino Jr 1998 Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group Stat Med. 17 2265 2281 9802183 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0. CO;2-B (Pubitemid 28466823)
28. DB Rubin 2007 The design versus the analysis of observational studies for causal effects: parallels with the design of randomized trials Stat Med. 26 20 36 17072897 10.1002/sim.2739 (Pubitemid 46099415)
29. AL Gleisner MA Choti L Assumpcao, et al. 2008 Colorectal liver metastases: recurrence and survival following hepatic resection, radiofrequency ablation, and combined resection-radiofrequency ablation Arch Surg. 143 1204 1212 19075173 10.1001/archsurg.143.12.1204
30. DA Osborne EE Zervos J Strosberg, et al. 2006 Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors Ann Surg Oncol. 13 572 581 16511671 10.1245/ASO.2006.03.071
31. J Bruix M Sherman JM Llovet, et al. 2001 Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver J Hepatol. 35 421 430 11592607 10.1016/S0168-8278(01)00130-1 1:STN:280:DC%2BD3MrksFCmtg%3D%3D (Pubitemid 32844200)
32. A Forner C Ayuso M Varela, et al. 2009 Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer. 115 616 623 19117042 10.1002/cncr.24050